New Experimental Nasal TB Vaccine Shows Promise in Early Research

Scientists have developed an experimental nasal TB vaccine that has produced encouraging results in early animal studies, offering a potential new approach to preventing and treating tuberculosis. The findings, published in the Journal of Clinical Investigation, could support global efforts to improve protection against one of the world’s deadliest infectious diseases.

The research comes as tuberculosis (TB) remains a major global health challenge. According to experts, TB became the leading cause of death from a single infectious pathogen in 2024, surpassing COVID-19. The World Health Organization (WHO) has been supporting the development of new vaccines to strengthen current treatment strategies and reduce the disease’s global impact.

New Vaccine Targets TB Survival Mechanism

Researchers at Johns Hopkins University developed the experimental DNA-based nasal vaccine by combining two genes, relMtb and Mip3α.

According to the research team, the relMtb gene produces a protein that helps tuberculosis bacteria survive under stressful conditions, including antibiotic exposure, low oxygen levels and limited nutrients. The vaccine is designed to target this survival mechanism and trigger a stronger immune response against the bacteria.

Why New TB Vaccines Are Needed

Current antibiotic treatment for tuberculosis is generally effective but requires patients to complete a complex six-month course of medication. Health experts say the lengthy treatment can lead to incomplete therapy, increasing the risk of disease relapse and antibiotic resistance.

The WHO continues to encourage the development of new vaccines that could improve treatment outcomes and potentially shorten the duration of therapy.

Human Trials Still Needed

The promising results have so far been observed only in animal studies. Researchers say further clinical trials in humans will be necessary to determine whether the vaccine is safe and effective for widespread use.

If future studies confirm these findings, the experimental nasal vaccine could represent an important advance in the prevention and treatment of tuberculosis.

Also Read : Government To Launch HIV Screening In Karachi Areas After Reported Spread